IP Library Granted Patent US 9,506,036
Granted Patent B2
US 9,506,036 · App. 13/211,951 · Granted Nov 29, 2016

Differentiation of human embryonic stem cells

Inventor: Benjamin Fryer (Skillman, NJ)
Assignee: Janssen Biotech, Inc.
C12N5/0678C12N2500/34C12N2501/115C12N2501/19C12N2501/727C12N2506/02C12N2533/54
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,506,036
App. No.
13/211,951
Granted
Nov 29, 2016
Kind
B2
Abstract

The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method to produce a population of cells, wherein greater than 80% of the cells in the population express markers characteristic of the definitive endoderm lineage.

Claims (19)

1. An in vitro culture comprising an isolated population of in vitro differentiated cells and a serum-free cell culture medium supplemented with L-alanyl-L-glutamine in which the concentration of glucose does not exceed 10.5 mM,

wherein greater than 80% of the cells in the population are definitive endoderm cells and express CXCR4 and CD99, and

wherein said population of cells is obtained by a step-wise differentiation process comprising:

(i) seeding clusters of pluripotent stem cells in a serum-free medium supplemented with L-alanyl-L-glutamine, and glucose at a concentration that does not exceed 10.5 mM;

(ii) culturing the pluripotent stem cells for about one day in a serum-free medium supplemented with L-alanyl-L-glutamine, about 100 ng/ml activin A, about 20 ng/ml of Wnt-3a, and glucose at a concentration that does not exceed 10.5 mM; followed by

(iii) culturing the cells for about three days in a serum-free medium supplemented with L-alanyl-L-glutamine, about 100 ng/ml activin A, and glucose at a concentration that does not exceed 10.5 mM, whereby the culture does not require further purification or selection of the definitive endoderm cells.

2. The isolated population of cells of claim 1 , wherein the concentration of glucose does not exceed 5.5 mM.

3. An in vitro culture comprising an isolated population of in vitro differentiated cells and a serum-free cell culture medium supplemented with L-alanyl-L-glutamine and glucose at a concentration that does not exceed 10.5 mM,

wherein greater than 80% of the cells in the population are definitive endoderm cells and express CXCR4 and, CD99, and

wherein said population of cells is obtained by a step-wise differentiation process comprising the steps of:

(i) seeding pluripotent stem cells in a serum-free medium supplemented with L-alanyl-L-glutamine and glucose at a concentration that does not exceed 10.5 mM,

(ii) culturing the pluripotent stem cells for about one day in a serum-free medium supplemented with L-alanyl-L-glutamine, about 100 ng/ml activin A, about 20 ng/ml Wnt-3a and glucose at a concentration that does not exceed 10.5 mM; followed by

(iii) culturing the cells for about three days in a serum-free medium supplemented with L-alanyl-L-glutamine, about 100 ng/ml activin A, and glucose at concentration that does not exceed 10.5 mM, whereby the culture does not require further purification or selection of the definitive endoderm cells.

4. The in vitro culture of claim 3 , wherein the concentration of glucose does not exceed 5.5 mM.

5. The in vitro culture of claim 3 , wherein the concentration of glucose in said step-wise differentiation process does not exceed 5.5 mM.

6. A method for generating a population of cells wherein 80% of the cells in the population are definitive endoderm cells and express CXCR4 and CD99, wherein said population of cells is obtained by a step-wise differentiation process comprising the steps of:

(i) seeding pluripotent stem cells in a serum-free medium supplemented with L-alanyl-L-glutamine and glucose at a concentration that does not exceed 10.5 mM,

(ii) culturing the pluripotent stern cells for about one day in a serum-free medium supplemented with L-alanyl-L-glutamine, about 100 ng/ml activin A, about 20 ng/ml Wnt-3a and glucose at a concentration that does not exceed 10.5 mM; followed by

(iii) culturing the cells for about three days in a serum-free medium supplemented with L-alanyl-L-glutamine, about 100 ng/ml activin A, and glucose at concentration that does not exceed 10.5 mM, whereby the culture does not require further purification or selection of the definitive endoderm cells.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2016
From: FRYER, BENJAMIN
To: JANSSEN BIOTECH, INC.
Reel/Frame 040047/0546 →
Continuity (2)
Provisional Application 61378448 · Aug 31, 2010
Related Publication 20120052571A1 · Mar 1, 2012